Effect of diacerein on kidney function, glucose and blod fat metabolism alteration and acute inflamation indicators in type 2 diabetic patients with kidney disease

Effect of diacerein on renal function, metabolic control and acute inflamatory parameters in type 2 diabetic patients with nephropaty - randomized clinical trial - : Diacereina trial on diabetes mellitus with nephropaty

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

REBEC

Registry ID

RBR-2tfwq3

Enrollment

Unknown

Registered

2016-11-07

Start date

2014-03-07

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mellitus Diabetes Diabetic nephropathy Kidney Failure, Chronic

Interventions

There are two groups: Experimental group 1: 35 patients with diabetes and chronic kidney disease will receive 01 capsule of diacerein 50 mg , oral, twice a day during 90 days. Control group: 35 pati

Drug

C18.452.394.750

C12.777.419.780.750.500

Eligibility

Age

30 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients from 30 to 80 years old, with type 2 diabetic with microalbuminuria. macroalbuniria and or diminished glomerular filtration rate (GFR - stages 1 and 2); HbA1c from 7.5 to 10%; in regular use of inhibitor Angiotensin Converting Enzyme or Angiotensin Receptor Blocker; Body mass index bellow 40kg / m²; do not make use of pioglitazone; Use of antihyperglycemic medications; Acceptance to participate and to sign informed consent; Patients seen in the outpatient medical clinic of the Faculdade de Medicina of Universidade de Passo Fundo

Exclusion criteria

Exclusion criteria: Pregnant and lactating women; presence of chronic inflammatory diseases such as arthritis, colitis; Infectious Disease like tuberculosis; use of anti-inflammatory drugs for more than five days in the last three months; previous diagnosis of pancreatitis; hypersensitivity to reigns or its correlates (laxative); Smoking; severe liver disease (transaminases major than 2.5 times the upper limit of normal); severe gastrointestinal disease; participation in another trial in the past 30 days; failure to follow the research protocol requirements

Design outcomes

Primary

Measure	Time frame
The primary outcomes were reduction ? 15% in ACR, any reduction in GFR, improvement of metabolic control (defined as A1C <7% and fasting glucose <126?mg/dL), reduction in plasma levels of IL-1, IL-6, IL-8, and TNF-?, increase in plasma levels of IL-10, and reduction in blood pressure.	—

Secondary

Measure	Time frame
Secondary outcomes included reduction in serum levels of fasting insulin, adiponectin, leptin, and selectin.	—

Countries

Brazil

Contacts

Public ContactSandra Fuchs

Universidade Federal do Rio Grande do Sul

scfuchs@terra.com.br+555133597621

Outcome results

None listed

Source: REBEC (via WHO ICTRP)